Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the EU / 2025-522801-39-00
Authorised, not yet recruiting Phase II

IFCT-2501 IDEATION ctDNA-guIDEd consolidATION immunotherapy after chemoradiotherapy in patients with stage III non-small cell lung cancer

2025-522801-39-00 · tracked via the Priya Life Science EU tracker
Sponsor
Intergroupe Francophone De Cancerologie Thoracique
Sponsor type
Patient organisation/association
Therapeutic area
Neoplasms
Decision date
02/07/2026
Enrollment target
177
Sites
France

Condition studied

Stage III Non Small Cell Lung Cancer

Investigational medicinal product(s)

IMFINZI 50 mg/mL concentrate for solution for infusion

Every trial of Durvalumab across our registers →

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male

Primary endpoint

12-month PFS rate from randomization as assessed by an independent review committee.

Endpoint detail

Investigator-assessed PFS from randomization, OS from randomization., Incidence, nature, and severity of adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 6.0 (NCI CTCAE v6.0)., Global and specific quality of life questionnaires QLQ-C30 QLQ-LC29 and EQ-5D-5L.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522801-39-00 on CTIS ↗ ← All trials in the EU